Mutation of RNA Polymerase β Subunit ( rpoB ) Promotes hVISA-to-VISA Phenotypic Conversion of Strain Mu3
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
The clinical vancomycin-intermediate Staphylococcus aureus (VISA) strain Mu50 carries two mutations in the vraSR and graRS two-component regulatory systems (TCRSs), namely, vraS(I5N ) and graR(N197S ) (hereinafter designated graR *). The clinical heterogeneously vancomycin-intermediate S. aureus (hVISA) strain Mu3 shares with Mu50 the mutation in vraS that encodes the VraS two-component histidine kinase. Previously, we showed that introduction of the plasmid p graR *, carrying the mutated two-component response regulator graR *, converted the hVISA strain Mu3 into VISA (vancomycin MIC = 4 mg/liter). Subsequently, however, we found that the introduction of a single copy of graR * into the Mu3 chromosome by a gene replacement method did not confer on Mu3 the VISA phenotype. The gene-replaced strain Mu3 graR * thus obtained remained hVISA (MIC ≤ 2 mg/liter), although a small increase in vancomycin MIC was observed compared to that of the parent strain Mu3. Reevaluation of the Mu3 and Mu50 genomes revealed the presence of another mutation responsible for the expression of the VISA phenotype in Mu50. Here, we demonstrate that in addition to the two regulator mutations, a third mutation found in the Mu50 rpoB gene, encoding the RNA polymerase β subunit, was required for Mu3 to achieve the level of vancomycin resistance of Mu50. The selection of strain Mu3 graR * with rifampin gave rise to rpoB mutants with various levels of increased vancomycin resistance. Furthermore, 3 (33%) of 10 independently isolated VISA strains established from the heterogeneous subpopulations of Mu3 graR * were found to possess rpoB mutations with or without an accompanying rifampin-resistance phenotype. The data indicate that a sizable proportion of the resistant hVISA cell subpopulations is composed of spontaneous rpoB mutants with various degrees of increased vancomycin resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility
Hiramatsu, K. (1997) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/40.1.135 · Cited by 1,984 · cited 2×
“The first hVISA clinical strain, Mu3, was isolated in January 1996, 4 months prior to the isolation of Mu50 in JUH (22). hVISA has a characteristic heterogeneous resistance phenotype as observed by analysis of the vancomycin-resistant cell subpopulations (population analysis) (22).”
BackgroundSelf-citationStructural Mechanism for Rifampicin Inhibition of Bacterial RNA Polymerase
Campbell, E. A., Korzheva, N., Mustaev, A., Murakami, K., Nair, S., Goldfarb, A., & Darst, S. A. (2001) · Cell · doi:10.1016/s0092-8674(01)00286-0 · Cited by 1,556 · cited 1×
“rifampin resistance-determining region (RRDR) of the rpoB gene (3, 47), with”
BackgroundEymann, C., Homuth, G., Scharf, C., & Hecker, M. (2002) · Journal of Bacteriology · doi:10.1128/jb.184.9.2500-2520.2002 · Cited by 306 · cited 1×
“These data indicated that the strain was in a stringent-response-like status (12).”
BackgroundImpact of rpoB Mutations on Reduced Vancomycin Susceptibility in Staphylococcus aureus
Watanabe, Y., Cui, L., Katayama, Y., Kozue, K., & Hiramatsu, K. (2011) · Journal of Clinical Microbiology · doi:10.1128/jcm.02144-10 · Cited by 127 · cited 1×
“We tested our collection of clinical VISA strains from various countries and found that this was the case: more than 70% of the VISA strains carried rpoB mutations (46).”
BackgroundSelf-citation
Cited by
Antimicrobial heteroresistance: An emerging field in need of clarity
El-Halfawy, O. M., & Valvano, M. A. (2015) · Clinical Microbiology Reviews · doi:10.1128/cmr.00058-14 · Cited by 489
Vancomycin resistance in Staphylococcus aureus
Appelbaum, P. C., & Bozdogan, B. (2004) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2004.03.004 · Cited by 485
Glycopeptide antibiotics: Back to the future
Butler, M. S., Hansford, K. A., Blaskovich, M. A. T., Halai, R., & Cooper, M. A. (2014) · The Journal of Antibiotics · doi:10.1038/ja.2014.111 · Cited by 303
Global spread of three multidrug-resistant lineages of Staphylococcus epidermidis
Lee, J. Y. H., Monk, I. R., Gonçalves da Silva, A., Seemann, T., Chua, K. Y. L., Kearns, A., Hill, R., Woodford, N., Bartels, M. D., Strommenger, B., et al. (2018) · Nature Microbiology · doi:10.1038/s41564-018-0230-7 · Cited by 299
Genomic Basis for Methicillin Resistance in Staphylococcus aureus
Hiramatsu, K., Ito, T., Tsubakishita, S., Sasaki, T., Takeuchi, F., Morimoto, Y., Katayama, Y., Matsuo, M., Kuwahara-Arai, K., Hishinuma, T., et al. (2013) · Infection & Chemotherapy · doi:10.3947/ic.2013.45.2.117 · Cited by 189
“aureus (hVISA) contain the cells with many different rpoB mutations [98].”
BackgroundSelf-citation
Metadata
- Authors
- Matsuo, M., Hishinuma, T., Katayama, Y., Cui, L., Kapi, M., & Hiramatsu, K.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2011-09
- Volume
- 55
- Issue
- 9
- Pages
- 4188-4195
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2046589125
- Cited by
- 101
- References
- 4
- FWCI
- 4.40
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mutation of RNA Polymerase β Subunit ( rpoB ) Promotes hVISA-to-VISA Phenotypic Conversion of Strain Mu3. https://app.cochat.ai/papers/10.1128/aac.00398-11
- The paper
- Matsuo, M., Hishinuma, T., Katayama, Y., Cui, L., Kapi, M., & Hiramatsu, K. (2011). Mutation of RNA Polymerase β Subunit ( rpoB ) Promotes hVISA-to-VISA Phenotypic Conversion of Strain Mu3. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00398-11
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.